SCHEMBL2646500

SCHEMBL2646500

O=Cc1c(CBr)ccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.55
MAPT P10636 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
GAA P10253 1/20 0.46
ADRB2 P07550 1/20 0.44
ADRB1 P08588 1/20 0.44
ALDH1A1 P00352 1/20 0.39
CYP2A6 P11509 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PTPN1 P18031 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2646726 0.83 ERN1 (0.61) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3268984 0.83 ERN1 (0.56) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL11335594 0.81 TDP1 (0.39) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL5841524 0.81 ERN1 (0.55) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL7110827 0.80 L3MBTL1 (0.58) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL5841800 0.79 ERN1 (0.51) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL6754178 0.79 ERN1 (0.56) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3269480 0.79 L3MBTL1 (0.55) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1484250 0.79 ERN1 (0.51) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL11764921 0.78 ERN1 (0.51) ERN1MAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4321604-A None JP disclosed
US-20250276993-A1 PSEUDO-DISACCHARIDE COMPOUNDS UNIVERSITEIT LEIDEN (NL) 2025-09-04 US disclosed
EP-4514813-A1 PSEUDO-DISACCHARIDE COMPOUNDS Universiteit Leiden (NL) 2025-03-05 EP disclosed
WO-2023211280-A1 PSEUDO-DISACCHARIDE COMPOUNDS UNIVERSITEIT LEIDEN (NL) 2023-11-02 WO disclosed
EP-1140823-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2001-10-10 EP disclosed
WO-2000039088-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-07-06 WO disclosed
JP-H04321604-A ANTIMICROBIAL AGENT COMPOSITION KURITA WATER IND LTD 1992-11-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276993-A1 PSEUDO-DISACCHARIDE COMPOUNDS HPSE, HEXD, HEXA ERN1 3248/4885MAPT 1544/4885CYP1A2 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.